Version 1
: Received: 18 March 2024 / Approved: 19 March 2024 / Online: 20 March 2024 (12:31:11 CET)
How to cite:
Falola, A.; Squire, H.; Bou-Antoun, S.; Løchen, A.; Brown, C.S.; Demirjian, A. COVID-19 Therapeutics Use by Social Deprivation in England, July 2020–April 2023. Preprints2024, 2024031157. https://doi.org/10.20944/preprints202403.1157.v1
Falola, A.; Squire, H.; Bou-Antoun, S.; Løchen, A.; Brown, C.S.; Demirjian, A. COVID-19 Therapeutics Use by Social Deprivation in England, July 2020–April 2023. Preprints 2024, 2024031157. https://doi.org/10.20944/preprints202403.1157.v1
Falola, A.; Squire, H.; Bou-Antoun, S.; Løchen, A.; Brown, C.S.; Demirjian, A. COVID-19 Therapeutics Use by Social Deprivation in England, July 2020–April 2023. Preprints2024, 2024031157. https://doi.org/10.20944/preprints202403.1157.v1
APA Style
Falola, A., Squire, H., Bou-Antoun, S., Løchen, A., Brown, C.S., & Demirjian, A. (2024). COVID-19 Therapeutics Use by Social Deprivation in England, July 2020–April 2023. Preprints. https://doi.org/10.20944/preprints202403.1157.v1
Chicago/Turabian Style
Falola, A., Colin S. Brown and Alicia Demirjian. 2024 "COVID-19 Therapeutics Use by Social Deprivation in England, July 2020–April 2023" Preprints. https://doi.org/10.20944/preprints202403.1157.v1
Abstract
Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor usage of COVID-19 therapeutics in hospital and community settings and inform stewardship. Three antiviral therapies: nirmatrelvir plus ritonavir (Paxlovid®), remdesivir (Veklury®), and molnupiravir (Lagevrio®); and two neutralising monoclonal antibody therapies (nMAbs): sotrovimab (Xevudy®) and casirivimab with imdevimab (Ronapreve®); were in use in England between July 2020 to April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report 2022 to 2023 also discusses the epidemiological surveillance of these five directly-acting antiviral COVID-19 therapeutics use in England between 2022 to 2023.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
